Literature DB >> 30877075

Outcomes and Treatment Strategies for Autoimmunity and Hyperinflammation in Patients with RAG Deficiency.

Jocelyn R Farmer1, Zsofia Foldvari2, Boglarka Ujhazi3, Suk See De Ravin4, Karin Chen5, Jack J H Bleesing6, Catharina Schuetz7, Waleed Al-Herz8, Roshini S Abraham9, Avni Y Joshi10, Beatriz T Costa-Carvalho11, David Buchbinder12, Claire Booth13, Andreas Reiff14, Polly J Ferguson15, Asghar Aghamohammadi16, Hassan Abolhassani16, Jennifer M Puck17, Mehdi Adeli18, Caterina Cancrini19, Paolo Palma20, Alice Bertaina21, Franco Locatelli22, Gigliola Di Matteo19, Raif S Geha23, Maria G Kanariou24, Lilia Lycopoulou25, Marianna Tzanoudaki24, John W Sleasman26, Suhag Parikh27, Gloria Pinero26, Bernard M Fischer26, Ghassan Dbaibo28, Ekrem Unal29, Turkan Patiroglu30, Musa Karakukcu29, Khulood Khalifa Al-Saad31, Meredith A Dilley32, Sung-Yun Pai33, Cullen M Dutmer34, Erwin W Gelfand35, Christoph B Geier36, Martha M Eibl37, Hermann M Wolf38, Lauren A Henderson39, Melissa M Hazen39, Carmem Bonfim40, Beata Wolska-Kuśnierz41, Manish J Butte42, Joseph D Hernandez43, Sarah K Nicholas44, Polina Stepensky45, Shanmuganathan Chandrakasan46, Maurizio Miano47, Emma Westermann-Clark48, Vera Goda49, Gergely Kriván49, Steven M Holland50, Olajumoke Fadugba51, Sarah E Henrickson52, Ahmet Ozen53, Elif Karakoc-Aydiner53, Safa Baris53, Ayca Kiykim54, Robbert Bredius55, Birgit Hoeger56, Kaan Boztug57, Olga Pashchenko58, Benedicte Neven59, Despina Moshous60, Jean-Pierre de Villartay61, Ahmed Aziz Bousfiha62, Harry R Hill63, Luigi D Notarangelo47, Jolan E Walter64.   

Abstract

BACKGROUND: Although autoimmunity and hyperinflammation secondary to recombination activating gene (RAG) deficiency have been associated with delayed diagnosis and even death, our current understanding is limited primarily to small case series.
OBJECTIVE: Understand the frequency, severity, and treatment responsiveness of autoimmunity and hyperinflammation in RAG deficiency.
METHODS: In reviewing the literature and our own database, we identified 85 patients with RAG deficiency, reported between 2001 and 2016, and compiled the largest case series to date of 63 patients with prominent autoimmune and/or hyperinflammatory pathology.
RESULTS: Diagnosis of RAG deficiency was delayed a median of 5 years from the first clinical signs of immune dysregulation. Most patients (55.6%) presented with more than 1 autoimmune or hyperinflammatory complication, with the most common etiologies being cytopenias (84.1%), granulomas (23.8%), and inflammatory skin disorders (19.0%). Infections, including live viral vaccinations, closely preceded the onset of autoimmunity in 28.6% of cases. Autoimmune cytopenias had early onset (median, 1.9, 2.1, and 2.6 years for autoimmune hemolytic anemia, immune thrombocytopenia, and autoimmune neutropenia, respectively) and were refractory to intravenous immunoglobulin, steroids, and rituximab in most cases (64.7%, 73.7%, and 71.4% for autoimmune hemolytic anemia, immune thrombocytopenia, and autoimmune neutropenia, respectively). Evans syndrome specifically was associated with lack of response to first-line therapy. Treatment-refractory autoimmunity/hyperinflammation prompted hematopoietic stem cell transplantation in 20 patients.
CONCLUSIONS: Autoimmunity/hyperinflammation can be a presenting sign of RAG deficiency and should prompt further evaluation. Multilineage cytopenias are often refractory to immunosuppressive treatment and may require hematopoietic cell transplantation for definitive management.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoimmune cytopenias; Hematopoietic stem cell transplantation (HSCT); Immune dysregulation; Recombination activating gene (RAG); Severe combined immunodeficiency (SCID)

Year:  2019        PMID: 30877075      PMCID: PMC6612449          DOI: 10.1016/j.jaip.2019.02.038

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  36 in total

1.  Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients.

Authors:  Delphine Gobert; James B Bussel; Charlotte Cunningham-Rundles; Lionel Galicier; Agnès Dechartres; Alice Berezne; Bernard Bonnotte; Thierry DeRevel; Christophe Auzary; Roland Jaussaud; Claire Larroche; Alain LeQuellec; Marc Ruivard; Pascal Seve; Amar Smail; Jean-François Viallard; Bertrand Godeau; Olivier Hermine; Marc Michel
Journal:  Br J Haematol       Date:  2011-10-08       Impact factor: 6.998

2.  Hypomorphic Rag mutations can cause destructive midline granulomatous disease.

Authors:  Suk See De Ravin; Edward W Cowen; Kol A Zarember; Narda L Whiting-Theobald; Douglas B Kuhns; Netanya G Sandler; Daniel C Douek; Stefania Pittaluga; Pietro L Poliani; Yu Nee Lee; Luigi D Notarangelo; Lei Wang; Frederick W Alt; Elizabeth M Kang; Joshua D Milner; Julie E Niemela; Mary Fontana-Penn; Sara H Sinal; Harry L Malech
Journal:  Blood       Date:  2010-05-20       Impact factor: 22.113

3.  A variant of SCID with specific immune responses and predominance of gamma delta T cells.

Authors:  Stephan Ehl; Klaus Schwarz; Anselm Enders; Ulrich Duffner; Ulrich Pannicke; Joachim Kühr; Françoise Mascart; Annette Schmitt-Graeff; Charlotte Niemeyer; Paul Fisch
Journal:  J Clin Invest       Date:  2005-10-06       Impact factor: 14.808

4.  Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors.

Authors:  Matthias Kreuzaler; Melanie Rauch; Ulrich Salzer; Jennifer Birmelin; Marta Rizzi; Bodo Grimbacher; Alessandro Plebani; Vassilios Lougaris; Isabella Quinti; Vojtech Thon; Jiri Litzman; Michael Schlesier; Klaus Warnatz; Jens Thiel; Antonius G Rolink; Hermann Eibel
Journal:  J Immunol       Date:  2011-11-28       Impact factor: 5.422

5.  Idiopathic CD4+ T lymphopenia without autoimmunity or granulomatous disease in the slipstream of RAG mutations.

Authors:  Taco W Kuijpers; Hanna Ijspeert; Ester M M van Leeuwen; Machiel H Jansen; Mette D Hazenberg; Kees C Weijer; Rene A W van Lier; Mirjam van der Burg
Journal:  Blood       Date:  2011-04-18       Impact factor: 22.113

6.  Highly variable clinical phenotypes of hypomorphic RAG1 mutations.

Authors:  Elizabeth Mannino Avila; Gulbu Uzel; Amy Hsu; Joshua D Milner; Maria L Turner; Stefania Pittaluga; Alexandra F Freeman; Steven M Holland
Journal:  Pediatrics       Date:  2010-10-18       Impact factor: 7.124

7.  Expansion of immunoglobulin-secreting cells and defects in B cell tolerance in Rag-dependent immunodeficiency.

Authors:  Jolan E Walter; Francesca Rucci; Laura Patrizi; Mike Recher; Stephan Regenass; Tiziana Paganini; Marton Keszei; Itai Pessach; Philipp A Lang; Pietro Luigi Poliani; Silvia Giliani; Waleed Al-Herz; Morton J Cowan; Jennifer M Puck; Jack Bleesing; Tim Niehues; Catharina Schuetz; Harry Malech; Suk See DeRavin; Fabio Facchetti; Andrew R Gennery; Emma Andersson; Naynesh R Kamani; JoAnn Sekiguchi; Hamid M Alenezi; Javier Chinen; Ghassan Dbaibo; Gehad ElGhazali; Adriano Fontana; Srdjan Pasic; Cynthia Detre; Cox Terhorst; Frederick W Alt; Luigi D Notarangelo
Journal:  J Exp Med       Date:  2010-06-14       Impact factor: 14.307

Review 8.  Genetically determined lymphopenia and autoimmune manifestations.

Authors:  Anna Villa; Veronica Marrella; Francesca Rucci; Luigi D Notarangelo
Journal:  Curr Opin Immunol       Date:  2008-04-09       Impact factor: 7.486

9.  An immunodeficiency disease with RAG mutations and granulomas.

Authors:  Catharina Schuetz; Kirsten Huck; Sonja Gudowius; Mosaad Megahed; Oliver Feyen; Bernd Hubner; Dominik T Schneider; Burkhard Manfras; Ulrich Pannicke; Rein Willemze; Ruth Knüchel; Ulrich Göbel; Ansgar Schulz; Arndt Borkhardt; Wilhelm Friedrich; Klaus Schwarz; Tim Niehues
Journal:  N Engl J Med       Date:  2008-05-08       Impact factor: 91.245

10.  A novel immunodeficiency associated with hypomorphic RAG1 mutations and CMV infection.

Authors:  Jean-Pierre de Villartay; Annick Lim; Hamoud Al-Mousa; Sophie Dupont; Julie Déchanet-Merville; Edith Coumau-Gatbois; Marie-Lise Gougeon; Arnaud Lemainque; Céline Eidenschenk; Emmanuelle Jouanguy; Laurent Abel; Jean-Laurent Casanova; Alain Fischer; Françoise Le Deist
Journal:  J Clin Invest       Date:  2005-11       Impact factor: 14.808

View more
  26 in total

1.  Primary immunodeficiencies: novel genes and unusual presentations.

Authors:  Luigi D Notarangelo; Gulbu Uzel; V Koneti Rao
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 2.  Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs).

Authors:  Markus G Seidel
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 3.  Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs.

Authors:  Elissa R Engel; Jolan E Walter
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

4.  Analysis of five cases of monogenic lupus related to primary immunodeficiency diseases.

Authors:  Gaixiu Su; Jianming Lai; Jia Zhu; Dan Zhang; Jun Hou; Yingjie Xu; Zhixuan Zhou
Journal:  Inflamm Res       Date:  2021-09-24       Impact factor: 4.575

Review 5.  Immune dysregulation in patients with RAG deficiency and other forms of combined immune deficiency.

Authors:  Ottavia M Delmonte; Anna Villa; Luigi D Notarangelo
Journal:  Blood       Date:  2020-02-27       Impact factor: 22.113

6.  Molecular diagnosis of childhood immune dysregulation, polyendocrinopathy, and enteropathy, and implications for clinical management.

Authors:  Sarah K Baxter; Tom Walsh; Silvia Casadei; Mary M Eckert; Eric J Allenspach; David Hagin; Gesmar Segundo; Ming K Lee; Suleyman Gulsuner; Brian H Shirts; Kathleen E Sullivan; Michael D Keller; Troy R Torgerson; Mary-Claire King
Journal:  J Allergy Clin Immunol       Date:  2021-04-20       Impact factor: 10.793

7.  Clinical Manifestations, Mutational Analysis, and Immunological Phenotype in Patients with RAG1/2 Mutations: First Cases Series from Mexico and Description of Two Novel Mutations.

Authors:  Saul Oswaldo Lugo-Reyes; Nina Pastor; Edith González-Serrano; Marco Antonio Yamazaki-Nakashimada; Selma Scheffler-Mendoza; Laura Berron-Ruiz; Guillermo Wakida; Maria Enriqueta Nuñez-Nuñez; Ana Paola Macias-Robles; Aide Tamara Staines-Boone; Edna Venegas-Montoya; Carmen Alaez-Verson; Carolina Molina-Garay; Luis Leonardo Flores-Lagunes; Karol Carrillo-Sanchez; Julie Niemela; Sergio D Rosenzweig; Paul Gaytan; Jorge A Yañez; Ivan Martinez-Duncker; Luigi D Notarangelo; Sara Espinosa-Padilla; Mario Ernesto Cruz-Munoz
Journal:  J Clin Immunol       Date:  2021-05-05       Impact factor: 8.317

8.  Primary Immunodeficiency in Children With Autoimmune Cytopenias: Retrospective 154-Patient Cohort.

Authors:  Emma Westermann-Clark; Cristina Adelia Meehan; Anna K Meyer; Joseph F Dasso; Devendra Amre; Maryssa Ellison; Bhumika Patel; Marisol Betensky; Charles Isaac Hauk; Jennifer Mayer; Jonathan Metts; Jennifer W Leiding; Panida Sriaroon; Ambuj Kumar; Irmel Ayala; Jolan E Walter
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

9.  Gene Editing Rescues In vitro T Cell Development of RAG2-Deficient Induced Pluripotent Stem Cells in an Artificial Thymic Organoid System.

Authors:  Cameron L Gardner; Mara Pavel-Dinu; Kerry Dobbs; Marita Bosticardo; Paul K Reardon; Justin Lack; Suk See DeRavin; Kent Le; Ezekiel Bello; Francesca Pala; Ottavia M Delmonte; Harry Malech; Amelie Montel-Hagan; Gay Crooks; Oreste Acuto; Matthew H Porteus; Luigi D Notarangelo
Journal:  J Clin Immunol       Date:  2021-03-01       Impact factor: 8.542

Review 10.  DNA Damage Response in the Adaptive Arm of the Immune System: Implications for Autoimmunity.

Authors:  Theodora Manolakou; Panayotis Verginis; Dimitrios T Boumpas
Journal:  Int J Mol Sci       Date:  2021-05-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.